I would add that, unfortunately, medicinal chemistry is increasingly regarded as a commodity in the life sciences field. And, worse, it's subject to substantial price competition from CROs in Asia. That -- and the ongoing hemmorhaging of jobs from large pharma companies -- is making jobs for bench-level chemists a bit more scarce. I worry, though, because it's the bench-level chemists who grow up and gather the experience to become effective managers of out-sourced chemistry, and I'm concerned that we may be losing that next general of great drug discovery chemists.I wish I could disagree with any of this, but I really can't.
Thursday, November 19, 2015
In a recent Reddit AMA, Michael Gilman, the CEO of Padlock Therapeutics in Cambridge, opines on the future of medicinal chemistry in the United States: